Abstract
Characterisation of outcomes and costs of haemophilia care in common practice settings is essential for evaluation of new treatment options and for developing clinical practices. In Finland, haemophilia care is mostly centralised to University Hospitals, but treatment practices and costs in adult patients have not been systematically evaluated. This study was designed to characterise healthcare resource utilisation and treatment costs of adult inhibitor-negative haemophilia patients managed in Finnish University Hospitals. The study was based on a nationwide cohort, which consists of all adult haemophilia A (HA; n = 120) and B (HB; n = 35) patients treated in University Hospitals from 2012 to 2016. Patient characteristics and data on healthcare utilisation and factor replacement use were collected from medical records. Direct costs of care were evaluated based on wholesale drug prices and healthcare service utilisation with standard unit costs. Most of HA (79%, n = 96) and HB (84%, n = 31) patients received factor replacement therapy. The median annual bleeding rate (ABR) was low, at 0.8 for HA and 0.5 for HB, also among the patients with on-demand therapy. Over 94% (n = 149) of the patients had outpatient visits during the fol...Continue Reading
References
Feb 6, 2008·Haemophilia : the Official Journal of the World Federation of Hemophilia·B T ColvinUNKNOWN Inter Disciplinary Working Group
Oct 23, 2009·Haemophilia : the Official Journal of the World Federation of Hemophilia·M N D Di MinnoA Coppola
Jul 9, 2010·Haemophilia : the Official Journal of the World Federation of Hemophilia·M A Escobar
Dec 14, 2011·Haemophilia : the Official Journal of the World Federation of Hemophilia·S GuhJ M Soucie
Jul 11, 2012·Haemophilia : the Official Journal of the World Federation of Hemophilia·A SrivastavaUNKNOWN Treatment Guidelines Working Group on Behalf of The World Federation Of Hemophilia
Jun 20, 2013·Blood·Kathelijn FischerErik Berntorp
Mar 7, 2014·Journal of Health Economics·Gustav KjellssonUlf-G Gerdtham
Aug 12, 2014·Journal of Medical Economics·Edward P ArmstrongMaj Jacob Wessler
Feb 11, 2015·Journal of Medical Economics·Zheng-Yi ZhouMichael B Nichol
Oct 28, 2015·BMC Health Services Research·Patrícia RochaFernando Araújo
Oct 22, 2016·Thrombosis Journal·Man-Chiu Poon, Adrienne Lee
Feb 12, 2017·Blood·Marilyn J Manco-JohnsonUNKNOWN Joint Outcomes Committee of the Universal Data Collection, US Hemophilia Treatment Center Network
May 19, 2017·Haemophilia : the Official Journal of the World Federation of Hemophilia·M ScottC R M Hay
Jun 2, 2017·Orphanet Journal of Rare Diseases·Jamie O'HaraDaniel-Anibal Garcia Diego
Jun 3, 2017·Haemophilia : the Official Journal of the World Federation of Hemophilia·A ShresthaK Batt
Oct 2, 2017·Value in Health : the Journal of the International Society for Pharmacoeconomics and Outcomes Research·Christina X ChenMichael B Nichol
Oct 12, 2017·Blood·Valder R ArrudaBenjamin J Samelson-Jones
Mar 2, 2018·Haemophilia : the Official Journal of the World Federation of Hemophilia·K VepsäläinenJ Martikainen